CJC-1295 vs Tesamorelin | Research Comparison

CJC-1295 No DAC and Tesamorelin are both synthetic GHRH analogues that stimulate GH release via GHRH receptor activation. Despite sharing the same receptor target, they differ significantly in sequence length, structural modifications, stability profile and primary research applications. This comparison helps researchers understand which compound is more appropriate for specific experimental designs.

At a Glance

Shared Mechanism

Both CJC-1295 No DAC and Tesamorelin bind to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion. Both are engineered to resist DPP-IV degradation — the primary enzyme responsible for rapid inactivation of native GHRH — though they achieve this through different structural strategies. Both activate downstream GH/IGF-1 axis signalling in laboratory models.

Key Structural Differences

Sequence Length

Tesamorelin retains the full 44-amino-acid sequence of endogenous GHRH, preserving all native receptor contact points. CJC-1295 No DAC uses only the first 29 amino acids (the minimum required for GHRHR activation) with four stabilising substitutions. In laboratory research, the full-length sequence of Tesamorelin may confer slightly different receptor binding kinetics compared to the truncated CJC-1295 sequence.

Stabilisation Strategy

CJC-1295 No DAC achieves DPP-IV resistance through amino acid substitutions at positions 2, 8, 11 and 13. Tesamorelin uses a trans-3-hexenoic acid conjugation at the N-terminus to block DPP-IV cleavage while preserving the native GHRH sequence. These different stabilisation approaches make them useful comparative tools for studying how structural modifications affect GHRHR binding and downstream signalling in vitro.

Research Application Differences

CJC-1295 No DAC

CJC-1295 is primarily used in laboratory research studying GH pulse dynamics, GHRHR pharmacology and GH secretagogue synergy. It is the standard companion to Ipamorelin in dual-receptor GH secretagogue research designs, where combined GHRHR and GHS-R1a activation is studied. It is preferred in models where pulsatile GH secretion patterns are the primary endpoint.

Tesamorelin

Tesamorelin is primarily used in laboratory research investigating visceral adipose tissue (VAT) regulation, GH-mediated lipolysis and hypothalamic-pituitary axis function. Its full-length GHRH sequence makes it a closer structural analogue to endogenous GHRH, which may be relevant in models studying native GHRH receptor interactions. It is used as a standalone GHRHR agonist rather than in combination protocols.

Choosing Between Them for Research

For GH pulse dynamics and combination secretagogue research (with Ipamorelin), CJC-1295 No DAC is the standard choice. For research focused on visceral adipose tissue, GH-mediated metabolic effects or full-length GHRH receptor pharmacology, Tesamorelin is more appropriate. Both are available from Solatide Biosciences, independently third-party tested to ≥99% purity.

Related Resources